Valuation: NetraMark Holdings Inc.

Market Cap 6.15Cr 4.45Cr 3.82Cr 3.55Cr 3.27Cr 426.49Cr 6.25Cr 42Cr 16Cr 214.02Cr 17Cr 16Cr 704.13Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 6.15Cr 4.45Cr 3.82Cr 3.55Cr 3.27Cr 426.49Cr 6.25Cr 42Cr 16Cr 214.02Cr 17Cr 16Cr 704.13Cr EV / Sales 2026 *
153x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-3.77% - - 4.43Cr
+0.56%-3.87%-6.34%+53.03% 3,57600Cr
+2.13%+0.14%+0.67%+1,116.60% 41TCr
-0.49%-3.83%-11.58%+42.82% 8.72TCr
-5.07%-5.37%+80.93%+149.41% 8.83TCr
-0.78%-2.35%-35.84%-5.82% 7.74TCr
+2.44%-9.44%-32.81%+207.91% 7.12TCr
-2.21%-5.37%+1.93%+72.44% 4.53TCr
+6.89%+13.08%+2.99%-6.48% 4.13TCr
-4.41%-13.32%+111.20%+274.09% 3.56TCr
Average -0.35%-3.33%+12.35%+211.55% 49.28TCr
Weighted average by Cap. +0.15%-4.07%-3.88%+156.49%

Financials

2026 *2027 *
Net sales 4L 3L 2L 2L 2L 2.78Cr 4L 27.37L 10.7L 1.4Cr 10.9L 10.67L 4.59Cr -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-

Quarterly revenue - Rate of surprise